Feiba Dosage & Drug Information

Concise Prescribing Info

Contents

Human plasma protein w/ a Factor VIII Inhibitor Bypassing Agent

Indications/Uses

Treatment & prophylaxis of bleeding in hemophilia A & B patients w/ inhibitor & in non-hemophiliacs w/ acquired inhibitors to factors VIII, XI & XII.

Dosage/Direction for Use

Dosage & duration of therapy depend on severity of the disorder of haemostasis & location of bleeding. 50-100 U/kg body wt bid. Max: 200 U/kg body wt.

Contraindications

Disseminated intravascular coagulation (DIC), MI, acute thrombosis &/or embolism.

Special Precautions

Hypersensitivity reactions (discontinue). Minor reactions may be controlled by antihistamines. In case of shock, current medical standards for treatment are to be observed.

Adverse Reactions

Rarely, DIC, MI, numbness, hypersensitivity, thromboembolic complication.

View ADR Monitoring Form

Drug Interactions

If indicated, Feiba & antifibrinolytics eg, aminocaproic acid may be given 6 hr apart.

MIMS Class

Haemostatics

ATC Classification

B02BD02 - coagulation factor VIII ; Belongs to the class of blood coagulation factors. Used in the treatment of hemorrhage.

Thai FDA Category

Presentation/Packing

Form

Feiba inj 1000 IU

Packing/Price

1's

Form

Feiba inj 500 IU

Packing/Price

1's

Feiba

Manufacturer:

Takeda

Distributor:

Zuellig Pharma